Rapidly Identifying HCPs Treating AML: The Lab Data Advantage

Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the overproduction of immature myeloid cells. With a five-year survival rate of just 27%, timely diagnosis and treatment are critical. This urgency underscores the importance of quickly identifying healthcare professionals (HCPs) involved in AML care. Leveraging lab data offers a powerful solution to accelerate this process, enabling faster connections and improved patient outcomes.

Understanding AML: A Complex Landscape

AML arises from myeloid progenitor cells, which normally differentiate into white blood cells, red blood cells, and platelets. In AML, these immature cells, known as blasts, proliferate uncontrollably, crowding out healthy blood cells. AML is categorized into subtypes based on the French-American-British (FAB) system or the World Health Organization (WHO) classification. The WHO system further categorizes AML based on genetic abnormalities, myelodysplasia-related changes, therapy-related factors, and other uncommon subtypes. This complex classification highlights the need for precise diagnostic tools.

AML primarily affects adults, with the average age at diagnosis being 68. Symptoms can be non-specific, including fatigue, weight loss, fever, and bone pain, often delaying diagnosis. Definitive diagnosis relies on a combination of lab tests, including:

• Complete Blood Count (CBC) and Peripheral Blood Smear: These tests reveal abnormalities in blood cell counts and identify circulating blast cells.
• Bone Marrow Biopsy and Aspiration: Essential for confirming the diagnosis and monitoring treatment response, this procedure examines the bone marrow for the presence of blasts.
• Immunophenotyping and Cytogenetic Analysis: These tests distinguish AML from other leukemias and identify specific genetic abnormalities that influence prognosis and treatment decisions.
• Molecular Testing: Detects key genetic mutations, such as FLT3, NPM1, and IDH1/2, which are crucial for risk stratification and targeted therapy selection.

The Value of Lab Data in HCP Identification

Lab data plays a crucial role not only in diagnosing and classifying AML but also in identifying the HCPs involved in patient care. By analyzing lab results, Prognos Health can pinpoint HCPs who have ordered specific tests, such as bone marrow biopsies, cytogenetic analyses, or molecular testing for AML-related mutations. This data-driven approach offers several advantages:

• Faster Identification: Lab data provides a direct and efficient way to identify HCPs actively engaged in AML diagnosis and treatment, eliminating the need for time-consuming manual research.
• Targeted Outreach: Brands can use this information to tailor their communication and resources to the specific needs and interests of these HCPs.
• Improved Collaboration: Facilitating connections between pharmaceutical companies and relevant HCPs can improve patient access to clinical trials, new therapies, and educational resources.
• Enhanced Patient Outcomes: Ultimately, faster HCP identification can lead to quicker diagnoses, more appropriate treatment decisions, and improved outcomes for patients with AML.

Prognos Health's Precision Marketing Suite for AML

Prognos Health's precision marketing suite empowers pharmaceutical brands to effectively identify and engage with HCPs treating AML patients. By leveraging the power of lab data, our suite provides deep insights into HCP practice patterns, patient populations, and key events in the patient journey. This allows for highly targeted outreach, personalized communication, and improved collaboration between brands and HCPs. Our solutions enable faster HCP identification, ultimately accelerating the delivery of critical information and improving the lives of those affected by this challenging disease.

Looking to learn more about how Prognos Health can help? Email us directly at atriscuit@prognoshealth.com or submit our interest form here.